Dry Eye

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The product is expected to be available in stores and online at Amazon, CVS, Target and Walgreens by the end of June 2026.

Upsher-Smith launched generic cyclosporine ophthalmic emulsion 0.05% in the US for tear production in inflammatory dry eye.

Mitch Ibach, OD, FAAO; Nate Lighthizer, OD, FAAO; and Austin Lifferth, OD, FAAO, share practical insights on identifying early disease and more.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Jessilin Quint, OD, MBA, MS, FAAO, shares strategies for improving adherence, building trust through patient communication, and more.

Knowing the shared signs and symptoms can lead to proper diagnosis.

The videos provide an overview of the report, review the diagnostic methodology section, and highlight key points from the management and therapy report.

The launch is supported by results from a phase 3 randomized, double-masked, placebo-controlled trial (3-02).

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

The study demonstrates that Corynebacterium mastitidis, a bacterium that resides on the ocular surface, can be genetically modified to secrete the anti-inflammatory cytokine interleukin-10.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.

Previously, the company received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED.

Examining the physiologic limits and patient selection for warm compress therapy in meibomian gland dysfunction can help identify when its usage may be ineffective.

The study highlights the broader impact of OR on patients’ quality of life.

Amniotic membrane therapy has been used in refractory cases to protect the ocular surface, modulate inflammation and fibrosis, and promote epithelial healing.

Mile Brujic, OD, FAAO, presented data from a study in February 2026 that examined real-world experience with lifitegrast across 12 offices—6 ophthalmology and 6 optometry practices.

The review notes aesthetic considerations are increasingly important as social media and video conferencing spotlight facial appearance.

Clocking in for Workplace Eye Wellness Month means knowing the environmental factors contributing to a patient's dry eye.

Rachon, OD, FAAO, DipABO, details her SECO 2026 poster presentation, "Treatment of Stage 1 NK Secondary to Acoustic Neuroma Removal with Cryopreserved Amniotic Membrane."

According to a VSP Vision Care news release, 71% say they experience performance impacts due to screen-related visual discomfort, equating to nearly one full workday of lost productivity each week.

A handful of MDs detail their presentations at this year's conference.

Rahul S. Tonk, MD, MBA, discussed his session on dry eye disease at EnVision Summit 2026, and looked ahead at the pipeline of therapies in development.